The CDC has recommended the use of a lab-made antibody, nirsevimab, as a primary option to protect newborns from severe RSV. This single-dose injection is approved for infants younger than 8 months entering their first RSV season. The agency also endorsed a maternal vaccine strategy, creating two distinct immunization pathways to guard infants against the respiratory virus.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.